Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases, announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behcet's disease. This designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval.
"We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program," said Soligenix CEO and president Christopher J. Schaber, PhD. Behcet's disease is an area of unmet medical need, with limited treatment options available.
Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body's innate immune system rather than suppress it outright. For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the EMA not only validates a drug's scientific rationale but can also unlock development incentives that accelerate its path forward.
The EMA's positive opinion signifies an important step for Soligenix as it continues to advance the program. The company's focus on rare diseases and areas of unmet medical need positions dusquetide as a potential therapy for Behcet's disease, a chronic condition characterized by inflammation of blood vessels.
More detailed information about the company and its developments can be found in its newsroom at https://ibn.fm/SNGX.
